LncRNA MIR4435-2HG、miR-125b-5p表达在非小细胞肺癌抗PD-1疗效和预后评估中的价值  

Significances of LncRNA MIR4435-2HG and miR-125b-5p in evaluating the efficacy and prognosis of anti PD-1 therapy in non-small cell lung cancer

作　　者：郝丽云 苏雅星 张馨月[2] Hao Liyun;Su Yaring;Zhang Xinyue(Department of Respiratory and Critical Care Medicine,Yan'an People's Hospital,Yan'an 716000,China;Department of General Practice Medicine,Yan'an People's Hospital,Yan'an 716000,China)

机构地区：[1]延安市人民医院呼吸与危重症医学科,延安716000 [2]延安市人民医院全科医学科,延安716000

出　　处：《国际呼吸杂志》2024年第7期808-815,共8页International Journal of Respiration

摘　　要：目的分析长链非编码RNA MIR4435-2宿主基因(LncRNA MIR4435-2HG)、微小RNA-125b-5p(miR-125b-5p)在非小细胞肺癌(NSCLC)患者抗程序性死亡受体1(PD-1)疗效和预后评估中的价值。方法本研究为队列研究。采用目的抽样法纳入2022年2月至2023年2月延安市人民医院确诊的96例NSCLC患者作为NSCLC患者组, 以及同期的健康体检人群96名为健康对照组。将96例NSCLC患者根据接受抗PD-1治疗6周后的疗效分为有效组(54例)和无效组(42例), 根据1年预后分为生存组(32例)和死亡组(64例)。采用starbase网站预测LncRNA MIR4435-2HG与miR-125b-5p的靶向关系。比较NSCLC患者组与健康对照组的血清LncRNA MIR4435-2HG、miR-125b-5p水平。比较有效组与无效组患者血清LncRNA MIR4435-2HG、miR-125b-5p水平和PD-L1表达情况。采用Spearman法分析治疗无效NSCLC患者血清LncRNA MIR4435-2HG、miR-125b-5p与PD-L1表达的相关性。分析NSCLC患者血清LncRNA MIR4435-2HG、miR-125b-5p与临床特征(性别、年龄、病理类型、肿瘤长径、TNM分期、分化程度和淋巴结转移)的关系。比较生存组和死亡组患者的血清LncRNA MIR4435-2HG、miR-125b-5p水平。采用单因素和多因素Cox回归分析NSCLC患者预后影响因素。采用受试者操作特征曲线分析血清LncRNA MIR4435-2HG、miR-125b-5p对预后的预测价值。结果 NSCLC患者组中男58例, 女38例;年龄(60.42±10.75)岁, 年龄范围32~76岁。健康对照组中男54名, 女42名;年龄(60.81±10.13)岁, 年龄范围30~78岁。starbase网站预测结果显示, LncRNA MIR4435-2HG与miR-125b-5p存在靶向调节关系。NSCLC患者组血清LncRNA MIR4435-2HG水平高于健康对照组[(1.62±0.40)比(1.01±0.22), t=13.09], miR-125b-5p低于健康对照组[(0.65±0.17)比(1.02±0.23), t=12.68], 差异均有统计学意义(均P<0.001)。无效组血清LncRNA MIR4435-2HG水平和PD-L1阳性比例均高于有效组[(1.94±0.51)比(1.37±0.32), t=6.70;24例(57.14%)比3例(5.56%), χ^(2)=31.10], miR-125b-Objective:To analyze the value of long non-coding RNA MIR4435-2 host gene(LncRNA MIR4435-2HG)and microRNA-125b-5p(miR-125b-5p)in evaluating the efficacy and prognosis of anti-programmed death-1(PD-1)therapy in non-small cell lung cancer(NSCLC)patients.Methods:This was a cohort study retrospectively involving 96 NSCLC patients diagnosed in Yan′an People′s Hospital between February 2022 and February 2023 in the NSCLC group by objective sampling method.During the same period,96 healthy individuals undergoing physical examinations were regarded as the healthy control group.A total of 96 NSCLC patients were assigned into the effective group(54 cases)and ineffective group(42 cases)based on their efficacy of anti-PD-1 treatment after 6 weeks.Moreover,they were assigned into the survival group(32 cases)and death group(64 cases)based on their 1-year prognosis.The targeting relationship between LncRNA MIR4435-2HG and miR-125b-5p was predicted on Starbase.Serum LncRNA MIR4435-2HG and miR-125b-5p levels were compared between NSCLCgroup and healthy control group.Serum LncRNA MIR4435-2HG,miR-125b-5p,and PD-L1 levels were compared between the effective and ineffective groups.Spearman′s correlation was used to analyze the correlation among serum LncRNA MIR4435-2HG,miR-125b-5p,and PD-L1 levelsin NSCLC patients of the ineffective group.The correlation of serum LncRNA MIR4435-2HG and miR-125b-5p with clinical features(gender,age,pathological type,tumor length,tumor-node-metastasis(TNM)staging,differentiation degree,and lymph node metastasis)in NSCLC patients was analyzed.Serum LncRNA MIR4435-2HG and miR-125b-5p levels between survival and death groups were compared.Univariate and multivariate Cox regression analyses were conducted to analyze the prognostic factors of NSCLC.Receiver operating characteristic(ROC)curve analysis was used to analyze the predictive value of serum LncRNA MIR4435-2HG and miR-125b-5p in the prognosis of NSCLC.Results:There were 58 males and 38 females in the NSCLC group,with a mean age of 60.42±10.75

关 键 词：癌 非小细胞肺 抗程序性死亡受体1治疗 长链非编码RNA MIR4435-2宿主基因 微小RNA-125b-5p 

分 类 号：R734.2[医药卫生—肿瘤]